CN102872149B - Application of Houttuynoid B in medicament for treating cecum cancer - Google Patents
Application of Houttuynoid B in medicament for treating cecum cancer Download PDFInfo
- Publication number
- CN102872149B CN102872149B CN 201210419692 CN201210419692A CN102872149B CN 102872149 B CN102872149 B CN 102872149B CN 201210419692 CN201210419692 CN 201210419692 CN 201210419692 A CN201210419692 A CN 201210419692A CN 102872149 B CN102872149 B CN 102872149B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- application
- cecum cancer
- treating
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of Houttuynoid B in a medicament for treating cecum cancer, and belongs to the technical field of new application of medicaments. In-vitro methyl thiazolyl tetrazolium (MTT) anti-tumor activity evaluation shows that the Houttuynoid B has a remarkable inhibiting effect on growth of a human cecum cancer cell line HCT-8. Therefore, the Houttuynoid B can be usedfor preparing the cecum cancer resistant medicament, and has a good development and application prospect. The invention discloses the application of the Houttuynoid B in preparation of the medicamentfor treating the cecum cancer for the first time, the skeleton type belongs to a brand-new skeleton type, and the Houttuynoid B has unexpected strong inhibiting activity on cecum cancer cells.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid B, relate in particular to the application of Houttuynoid B in the anti-ileocecum cancer drug of preparation.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the present reasonable antitumor drug of effect clinically such as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound H outtuynoid B that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid B_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this chemical compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid B_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes of the Houttuynoid B that the present invention relates in preparation treatment ileocecum cancer drug, because framework types belongs to brand-new framework types, and its inhibition for the ileocecum cancerous cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously the ileocecum cancer obviously has significant progress.
Summary of the invention
The invention provides the application of compound H outtuynoid B in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid B in the anti-ileocecum cancer drug of preparation, and the structural formula of Houttuynoid B is shown in formula I:
The present invention finds that by external MTT anti-tumor activity evaluation Houttuynoid B also has significant inhibitory action to the growth of human ileocecal carcinoma cell strain HCT-8, suppresses the IC of this 1 strain Growth of Cells
50Value is respectively 0.22 ± 0.07 μ M.Therefore, Houttuynoid B can for the preparation of anti-ileocecum cancer drug, have good development prospect.
The purposes of the Houttuynoid B that the present invention relates in preparation treatment ileocecum cancer drug belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for the ileocecum cancerous cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously the ileocecum cancer obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid B involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid B_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid B tablet involved in the present invention:
Get 20 and digest compound Houttuynoid B, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid B capsule involved in the present invention:
Get 20 and digest compound Houttuynoid B, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Houttuynoid B to the growth inhibited effect of human ileocecal carcinoma cell strain
1. method: the cell that is in the growth logarithmic (log) phase: human ileocecal carcinoma cell strain HCT-8(buys from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, 0.01 μ M, 0.001 μ M, the culture medium of the Houttuynoid B of 0.0001 μ M and 0.00001 μ M.After cultivating 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Houttuynoid B has significant inhibitory action to the growth of human ileocecal carcinoma cell strain HCT-8.This chemical compound suppresses the IC of human ileocecal carcinoma cell strain HCT-8 growth
50Value is respectively: 0.22 ± 0.07 μ M.
Shown that by above-described embodiment Houttuynoid B of the present invention has good inhibitory action to the growth of human ileocecal carcinoma cell strain HCT-8.Prove that thus it is active that Houttuynoid B of the present invention has anti-ileocecum cancer, can be for the preparation of anti-ileocecum cancer drug.
Claims (1)
1.Houttuynoid the application of B in preparation treatment ileocecum cancer drug, described compound H outtuynoid B structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210419692 CN102872149B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid B in medicament for treating cecum cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210419692 CN102872149B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid B in medicament for treating cecum cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102872149A CN102872149A (en) | 2013-01-16 |
| CN102872149B true CN102872149B (en) | 2013-10-16 |
Family
ID=47473820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210419692 Expired - Fee Related CN102872149B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid B in medicament for treating cecum cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102872149B (en) |
-
2012
- 2012-10-27 CN CN 201210419692 patent/CN102872149B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102872149A (en) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872149B (en) | Application of Houttuynoid B in medicament for treating cecum cancer | |
| CN102872095B (en) | Application of Houttuynoid E in medicine for treating ileocecum cancer | |
| CN102872150B (en) | Application of Houttuynoid B in medicament for treating prostatic cancer | |
| CN102872101B (en) | Application of Houttuynoid C in medicine for treating ileocecum cancer | |
| CN102872148B (en) | Application of Houttuynoid D in medicament for treating tongue cancer | |
| CN102872112B (en) | Application of Houttuynoid A in medicament for treating bladder cancer | |
| CN102861052B (en) | Application of Houttuynoid A in medicine for treating ileocecum cancer | |
| CN102872123B (en) | Application of Houttuynoid C in medicament for treating bladder cancer | |
| CN102872070B (en) | Application of Houttuynoid C to preparing drugs for treating prostate cancer | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102861084B (en) | Application of Houttuynoid D in medicine for treating ileocecum cancer | |
| CN102872109B (en) | Application of Houttuynoid A in medicament for treating prostate cancer | |
| CN102872072B (en) | Application of Houttuynoid B to preparing drugs for treating kidney cancer | |
| CN102872075A (en) | Application of Houttuynoid E in drugs for treating breast cancer | |
| CN102872089A (en) | Application of Houttuynoid E in medicines for treating skin cancer | |
| CN102872086A (en) | Application of Houttuynoid A in medicines for treating skin cancer | |
| CN102872151A (en) | Application of Houttuynoid B in medicament for treating nasopharyngeal cancer | |
| CN102885843A (en) | Application of Houttuynoid B in medicament for treating breast cancer | |
| CN102872088A (en) | Application of Houttuynoid D in medicines for treating nasopharyngeal carcinoma | |
| CN102895247A (en) | Application of Houttuynoid B to medicament for treating oophoroma | |
| CN102861051A (en) | Application of Houttuynoid A in medicine for treating renal cancer | |
| CN102895249A (en) | Application of Houttuynoid E to medicament for treating prostatic carcinoma | |
| CN102895248A (en) | Application of Houttuynoid A in drugs for treating laryngocarcinoma | |
| CN102872085A (en) | Application of Houttuynoid A in medicines for treating breast cancer | |
| CN102872102A (en) | Application of Houttuynoid C in medicine for treating breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: SONG HAIPING Free format text: FORMER OWNER: WU JUNHUA Effective date: 20130904 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Song Haiping Inventor after: Liu Deliang Inventor after: Sun Jing Inventor after: Huang Chen Inventor after: Wu Junyi Inventor after: Wu Junhua Inventor before: Huang Chen Inventor before: Wu Junyi Inventor before: Wu Junhua |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 266071 QINGDAO, SHANDONG PROVINCE Free format text: CORRECT: INVENTOR; FROM: HUANG CHEN WU JUNYI WU JUNHUA TO: SONG HAIPING LIU DELIANG SUN JING HUANG CHEN WU JUNYI WU JUNHUA |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20130904 Address after: 266071 Shandong Province, Qingdao city Chenghai Road No. 4 Applicant after: Song Haiping Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Applicant before: Wu Junhua |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131016 Termination date: 20151027 |
|
| EXPY | Termination of patent right or utility model |